Linked Life Data

7103689

Source:http://linkedlifedata.com/resource/pubmed/id/7103689

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1982-9-10
pubmed:abstractText
Turisteron is a depot estrogen with an average biological half-life of six days. It has the advantage compared to other oral estrogens that it can be administered once a week p.o. Forty late postmenopausal patients with metastatic breast cancer received Turisteron. Overall 19 (47,5%) had a positive response. An objective remission rate (tumor regression of greater than 50%) was achieved in 12 patients (30%). To date the mean duration of response is 27 months for complete remissions and 10 months for partial remissions. The risk-response relationship for Turisteron in older patients is favourable compared to that of polychemotherapy and it is therefore recommended that Turisteron be used as the initial therapy of choice for patients with metastatic breast cancer who are more than 5 years postmenopausal. Indications and contraindications for Turisteron are discussed in detail.
pubmed:language
ger
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0003-911X
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
129-39
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
[Clinical experience with the depot estrogen Turisteron in the treatment of metastatic breast cancer (author's transl)].
pubmed:publicationType
Journal Article, English Abstract